Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.
O Witt, S Farouk Sait, BD Diez, A Cardoso, DA Reardon… - 2024 - ascopubs.org
10002 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor
(FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally …
(FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally …
Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial: Exploratory …
3119 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor
(FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally …
(FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally …
Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in …
3007 Background: Erdafitinib (erda) is an oral selective pan-FGFR tyrosine kinase inhibitor
approved to treat locally advanced or metastatic urothelial carcinoma (UC) in adults with …
approved to treat locally advanced or metastatic urothelial carcinoma (UC) in adults with …
Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alterations: RAGNAR study pediatric cohort.
O Witt, B Geoerger, U Dirksen, S Farouk Sait… - 2022 - ascopubs.org
TPS10058 Background: FGFR gene alterations have been observed in pediatric patients
with cancers and represent potentially targetable genomic variants. Gliomas (high-and low …
with cancers and represent potentially targetable genomic variants. Gliomas (high-and low …
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).
A Lee, AJ Chou, PM Williams, S Roy-Chowdhuri… - 2023 - ascopubs.org
10007 Background: The NCI-Children's Oncology Group (COG) Pediatric Molecular
Analysis for Therapy Choice (MATCH) trial assigns patients aged 1-21 years with relapsed …
Analysis for Therapy Choice (MATCH) trial assigns patients aged 1-21 years with relapsed …
Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm …
O Carranza, MH Schuler, J Tabernero, Y Loriot… - 2024 - ascopubs.org
1088 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor
(FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally …
(FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally …
Phase II study of erdafitinib in patients with tumors with fibroblast growth factor receptor mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN trial …
PURPOSE Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-
label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral …
label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral …
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR …
MH Schuler, J Tabernero, O Carranza, Y Loriot, S Pant… - 2024 - ascopubs.org
8515 Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor
(FGFR) tyrosine kinase inhibitor approved in the US for treatment of locally advanced or …
(FGFR) tyrosine kinase inhibitor approved in the US for treatment of locally advanced or …
Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
JC Soria, A Italiano, A Cervantes… - Annals of …, 2016 - annalsofoncology.org
Background Erdafitinib (JNJ-42756493) is a potent, oral pan-FGFR tyrosine kinase inhibitor
that demonstrated encouraging preliminary clinical activity and manageable adverse events …
that demonstrated encouraging preliminary clinical activity and manageable adverse events …
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary …
3121 Background: FGFRalt are present across malignancies at various frequencies and
may act as oncogenic drivers across tissue histology. Erda is an oral selective pan-FGFR …
may act as oncogenic drivers across tissue histology. Erda is an oral selective pan-FGFR …
相关搜索
- efficacy and safety fgfr alterations
- efficacy and safety erdafitinib in adults
- pediatric patients fgfr alterations
- efficacy and safety pediatric patients
- safety of erdafitinib growth factor
- efficacy and safety open label
- safety of erdafitinib receptor alterations
- safety of erdafitinib interim analysis
- efficacy and safety breast cancer
- growth factor receptor alterations
- growth factor interim analysis
- efficacy of erdafitinib exploratory cohort
- inhibitor erdafitinib safety and activity
- erdafitinib in patients nci match
- erdafitinib in patients ecog acrin
- safety of erdafitinib fgfr alterations